GlassScriptPhysician profile
Nency Antoine
NPI 1457041097
$935.23
in general payments reported to CMS, 2019-2025
18 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $561 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $328.58 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $92.68 | 2025 | Krystexxa, Otezla, Repatha |
| Glaxosmithkline, LLC. | $64.35 | 2024 | Trelegy Ellipta |
| Corcept Therapeutics | $53.70 | 2024-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.43 | 2024-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $46.94 | 2024 | Airsupra, Bevespi Aerosphere |
| Exact Sciences Corporation | $45.47 | 2024 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $36.04 | 2025 | Opsumit, Uptravi |
| Sumitomo Pharma America, INC. | $27.05 | 2024 | Gemtesa |
| Dexcom, INC. | $26.97 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $23.42 | 2025 | Zoryve |
| Seqirus USA INC | $23.37 | 2025 | Flucelvax, Fluad |
| Pfizer INC. | $22.85 | 2025 | |
| Ardelyx, INC. | $22.50 | 2024 | Ibsrela |
| Eisai INC. | $20.22 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18.87 | 2025 | Mounjaro |
| Merck Sharp & Dohme LLC | $18.43 | 2025 | Capvaxive, Gardasil 9 |
| Watermark Medical, INC. | $14.36 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nency Antoine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.